BiotechTube

Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Atezolizumab Placebo + Paclitaxel

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple-Negative Breast Cancer

Conditions

Triple-Negative Breast Cancer

Trial Timeline

Aug 25, 2017 → Jan 17, 2023

NCT ID
NCT03125902

About Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Atezolizumab Placebo + Paclitaxel

Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Atezolizumab Placebo + Paclitaxel is a phase 3 stage product being developed by Roche for Triple-Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03125902. Target conditions include Triple-Negative Breast Cancer.

What happened to similar drugs?

1 of 6 similar drugs in Triple-Negative Breast Cancer were approved

Approved (1) Terminated (0) Active (5)
✅Taxane and Carboplatin + Short-term SintilimabInnovent BiologicsApproved
🔄Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
🔄Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for IpatasertibRochePhase 3
🔄Atezolizumab + Nab-PaclitaxelRochePhase 3
🔄Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Placebo + Nab-paclitaxel + Doxorubicin + Cyclophosphamide + Filgrastim + PegfilgrastimRochePhase 3
🔄AK112 + Nab-paclitaxel + PlaceboAkesoPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03125902Phase 3Completed

Competing Products

20 competing products in Triple-Negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Cisplatin + AZD1775AstraZenecaPhase 2
35
olaparib + DurvalumabAstraZenecaPhase 2
27
AZD2014 + AZD6244AstraZenecaPhase 1/2
28
OlaparibAstraZenecaPhase 1
29
Carboplatin + Docetaxel + Pembrolizumab + PegfilgrastimMerckPhase 2
39
Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
47
AN0025 + PembrolizumabMerckPhase 1
33
Pembrolizumab + AxatilimabMerckPhase 2
39
AE37 Peptide vaccine + PembrolizumabMerckPhase 2
31
Pembrolizumab + AxatilimabMerckPhase 2
42
Zilovertamab vedotinMerckPhase 2
27
Pembrolizumab + Paclitaxel + BevacizumabMerckPhase 2
42
OlinvacimabMerckPhase 2
27
Trilaciclib + Pembrolizumab + Gemcitabine + CarboplatinMerckPhase 2
39
LAG525 + PDR001 + CarboplatinNovartisPhase 2
35
Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for IpatasertibRochePhase 3
40
Atezolizumab + Nab-PaclitaxelRochePhase 3
40
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Placebo + Nab-paclitaxel + Doxorubicin + Cyclophosphamide + Filgrastim + PegfilgrastimRochePhase 3
40
Tiragolumab + Atezolizumab + Nab-paclitaxel + Tiragolumab + Atezolizumab + Nab-paclitaxel + Carboplatin + Doxorubicin + Cyclophosphamide + Granulocyte colony-stimulating factor (G-CSF) + Granulocyte-macrophage colony-stimulating factor (GM-CSF)RochePhase 1
29